Uwe Platzbecker
www.uniklinikum-leipzig.de
0000-0003-1863-3239
392 papers found
Refreshing results…
Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
Higher risk for chronic graft‐versus‐host disease ( GvHD ) in HLA‐G mismatched transplants following allogeneic hematopoietic stem cell transplantation: A retrospective study
Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
Outcome prediction by the knowledge bank approach in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantation
Analysis of stem cell collections in adult patients with Ewing sarcoma
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with intermediate-risk - results of the randomized ETAL-1 trial
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML
P1361: Treatment of Severe Steroid-Refractory Acute GVHD With Mesenchymal Stromal Cells: Results of the Phase Iii Randomized Double-Blind Multi-Center Hovon-113 Trial
S129: Takeaim Leukemia- A Phase 1/2a Study of the Irak4 Inhibitor Emavusertib (Ca-4948) as Monotherapy or in Combination With Azacitidine or Venetoclax in Relapsed/Refractory Aml or MDS
P1356: Patient-Specific Digital Droplet PCR Assays for Minimal Residual Disease Detection of Runx1 Mutations in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation
P1313: Predicting Outcomes in Aml Patients Consolidated by an Allogeneic Stem Cell Transplantation Using the Knowledge Bank Approach
P1381: Early Full Donor Chimerism After Flamsa Ric Based Allogeneic HSCT but Not Presence of Morphological Remission Associates With Outcomes in R/R Aml Patients
Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q): A Case Series
Missing publications? Search for publications with a matching author name.